A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical Oncology (ASCO), held May 30 through June 3 in Chicago.
This article was originally published on MedicalXpress.com